Pages Menu
Categories Menu

Posted by on Apr 24, 2015 in Foundation NewsLine |

04/24/2015 ~ Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts Pediatric Trial

Genzyme logo
Dear NNPDF Families and Friends,
The NNPDF Central Offices have been notified that Genzyme, a Sanofi Company, has released a statement with additional details about the pediatric Phase 1 / 2 clinical trial of recombinant human acid sphingomyelinase (rhASM).
Visit the NNPDF Enzyme Replacement Therapy web page to view the the statement:
Share this!

Please spread the word!